Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

However, we are pleased with the very positive controlled safety data from this trial which will be an essential part of our planned NDA submission of AXS-05 in Alzheimer’s disease agitation, which is ...

Axsome’s bid to market its option in Alzheimer’s disease, an area which has gained renewed interest thanks to the recent launch of novel therapeutics for the first time in decades, comes after US ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

Axsome Therapeutics said Monday it plans to seek FDA approval in Alzheimer’s disease agitation despite seeing mixed results in late-phase studies. The biotech reported data from two trials of AXS-05, ...

Viral infections may play a role in Alzheimer's disease. University of Pittsburgh researchers uncovered a surprising link between Alzheimer's disease and herpes simplex virus-1 (HSV-1), suggesting ...

University of Pittsburgh researchers uncovered a surprising link between Alzheimer's disease and herpes simplex virus-1 (HSV-1), suggesting that viral infections may play a role in the disease.

Get deeper insights into Axsome's financial health and growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro. The analysts' comments reflect a recognition of ...